Get the Stockscreener App
9.60
1.54%
-0.15
After Hours:
9.79
0.19
+1.98%
Immatics N V stock is traded at $9.60, with a volume of 286.14K.
It is down -1.54% in the last 24 hours and down -5.70% over the past month.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$9.75
Open:
$9.75
24h Volume:
286.14K
Relative Volume:
0.41
Market Cap:
$1.29B
Revenue:
$58.49M
Net Income/Loss:
$-105.04M
P/E Ratio:
-7.3863
EPS:
-1.2997
Net Cash Flow:
$-13.78M
1W Performance:
-4.67%
1M Performance:
-5.70%
6M Performance:
+68.13%
1Y Performance:
+31.87%
1-Day Range:
$9.56
$9.93
1-Week Range:
$9.13
$10.90
52-Week Range:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
9.60 | 1.31B | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics price target raised to $17 from $14 at BofA - TipRanks
Immatics (NASDAQ:IMTX) Stock Price Down 8.8%What's Next? - MarketBeat
Bank Watch: Will Immatics NV Equity Warrant stock deliver consistent dividendsJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - moha.gov.vn
Immatics (NASDAQ:IMTX) Upgraded at Wall Street Zen - Defense World
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy? - Defense World
Aug Analyst Calls: Why Immatics NV Equity Warrant stock could be next big winnerWeekly Profit Report & High Accuracy Trade Signal Alerts - moha.gov.vn
Immatics (NASDAQ:IMTX) Trading Up 3.9%Time to Buy? - MarketBeat
Analysis Recap: Why Immatics N.V. stock is rated strong buy2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn
Aug Final Week: Why Immatics NV stock remains on buy lists2025 Risk Factors & Long Hold Capital Preservation Tips - moha.gov.vn
Retail Surge: Is Immatics NV stock a top pick in earnings seasonTrade Performance Summary & Weekly Stock Breakout Alerts - moha.gov.vn
Aug Drivers: Is Immatics NV stock a top pick in earnings seasonQuarterly Profit Summary & Daily Growth Stock Tips - moha.gov.vn
(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
Why Immatics N.V. Equity Warrant stock appeals to dividend seekersTrend Reversal & Smart Allocation Stock Reports - Улправда
Is Immatics N.V. (4A3) stock a top dividend aristocrat candidate2025 Short Interest & Weekly Top Stock Performers List - Улправда
Aug Final Week: Can Immatics N.V. stock attract ESG capital inflowsWeekly Trade Review & Community Verified Swing Trade Signals - Улправда
Why hedge funds are buying Immatics N.V. stock2025 Buyback Activity & Reliable Entry Point Trade Alerts - Улправда
Why Immatics N.V. stock is rated strong buyJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Mizuho Securities Sticks to Their Buy Rating for Immatics (IMTX) - The Globe and Mail
Why Immatics N.V. stock is considered a top pickTrade Exit Report & Community Verified Watchlist Alerts - Улправда
Why Immatics N.V. (4A3) stock trades below fair valueJuly 2025 Price Swings & AI Optimized Trading Strategy Guides - Улправда
How Immatics N.V. Equity Warrant stock performs in rate cut cyclesM&A Rumor & Risk Adjusted Buy and Sell Alerts - DonanımHaber
How Immatics N.V. Equity Warrant stock reacts to Fed rate cutsInsider Selling & Comprehensive Market Scan Insights - DonanımHaber
How buybacks impact Immatics N.V. stock valueShort Setup & High Accuracy Trade Alerts - DonanımHaber
Can Immatics N.V. (4A3) stock test all time highsJuly 2025 Levels & Low Risk Investment Opportunities - DonanımHaber
How Immatics N.V. Equity Warrant stock compares to market leadersJuly 2025 Short Interest & Growth Oriented Trading Recommendations - DonanımHaber
Is Immatics N.V. stock a top pick in earnings seasonMarket Risk Report & Entry Point Strategy Guides - DonanımHaber
Bearish Setup: Why Immatics N.V. Equity Warrant stock could see breakout soonMarket Performance Summary & Capital Efficiency Focused Strategies - Улправда
Will Immatics N.V. Equity Warrant stock continue upward momentumJuly 2025 Earnings & Intraday High Probability Setup Alerts - DonanımHaber
Why Immatics N.V. Equity Warrant stock could see breakout soonWeekly Trade Review & Precise Trade Entry Recommendations - Улправда
Is Immatics N.V. Equity Warrant stock a buy for dividend growthIndex Update & Reliable Intraday Trade Alerts - Улправда
New Highs: Can Immatics N.V. stock attract ESG capital inflowsWeekly Stock Recap & Verified Swing Trading Watchlists - Улправда
Immatics appoints industry veteran as CFO - MSN
How Immatics’ US$125 Million Follow-on Equity Raise At Immatics (IMTX) Has Changed Its Investment Story - simplywall.st
Immatics completes $116.5 million share offering to boost R&D - MSN
(IMTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immatics (IMTX) Updates on Promising IMA203CD8 Cell Therapy Tria - GuruFocus
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress - TipRanks
Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial - TipRanks
Immatics Announces Promising Phase 1a Dose Escalation Results for IMA203CD8, a Second-Generation PRAME Cell Therapy for Advanced Solid Tumors - Quiver Quantitative
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - FinanzNachrichten.de
Is Immatics NV a good long term investmentMorning Star Patterns & Breakthrough Stock Performance - earlytimes.in
A look into Immatics N.V (IMTX)’s deeper side - setenews.com
Immatics Completes $116.5 Million Share Offering to Boost R&D - The Globe and Mail
Immatics announces offering of 12.5M ordinary shares - MSN
How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering - simplywall.st
Finance Watch: Biotech Investors Take FDA Turmoil In Stride - Citeline News & Insights
Immatics (NASDAQ:IMTX) Trading Up 8.9%Time to Buy? - MarketBeat
Immatics Down Nearly 15%, on Pace for Largest Percent Decrease Since October 2024 -- Data Talk - 富途牛牛
Immatics announces $125 million underwritten offering - marketscreener.com
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):